進行神経芽腫に対する統一プロトコールによる集学的治療の検討

フォーマット:

論文(リポジトリ)

責任表示:

岩渕, 眞 ; 大沢, 義弘 ; 内山, 昌則 ; 松田, 由紀夫 ; 内藤, 真一 ; 広田, 雅行 ; 内藤, 万砂文 ; 近藤, 公男 ; 内海, 治郎 ; 浅見, 恵子 ; 笹崎, 義博 ; 小田, 良彦 ; 佐藤, 雅久

出版情報:

新潟医学会, 1993-07

掲載情報:

新潟医学会雑誌 — 新潟医学会雑誌

ISSN:

00290440      

著者名:

岩渕, 眞

大沢, 義弘

内山, 昌則

松田, 由紀夫

内藤, 真一

広田, 雅行

内藤, 万砂文

近藤, 公男

内海, 治郎

浅見, 恵子

笹崎, 義博

小田, 良彦

佐藤, 雅久

続きを見る

巻:

107

通号:

7

開始ページ:

551

終了ページ:

558

概要:

Twenty-two pediatric patients with a stage IV-A or IV-B neuroblastoma have been treated with multimodal therapy consisting of intensive chemotherapy and surgery at Niigata University Hospital since 1985. The patients first received six cycl … ic courses of intensive chemotherapy ［regimen A_1］, consisting of cyclophosphamide ［1,200mg/m^2］, vincristine ［1.5mg/m^2], tetrahydropyranyl adriamycin ［pyrarubicin 40mg/m^2］, and cisplatin ［90mg/m^2］. Primary tumors and involved regional lymph nodes were removed sometime during first six cycles of chemotherapy. After the six cycles of ［Regiment A_1］, patients received alternating treatment with ［Regimen A_2］consisting of cyclophophamide ［1,500mg/m^2］, THP-adriamycin ［50mg/m^2］, cisplatin ［90mg/m^2］, and ［Regimen C］consisting of cyclophosphamide ［1,500mg/m^2］, DTIC ［250mg/m^2］. Two-year survival rate was 59%. Nine patients have now survived with disease free at 2 years after initiation of the treatment （survival rate: 41%）. From the viewpoint of prognosis, the influencing factors are as follows: small round cell type, diploidy, VMA（－）, NSE more than 100ng/ml, N-myc over 8 times of normal value. 続きを見る

E-Resources: